Andrew Baddoo, MD
Internal Medicine · West Orange, NJNPI 1881653608
Payments from drug & device makers
Across 682 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AstraZeneca$1K
- ANI Pharmaceuticals, Inc.$909
- Novo Nordisk$597
- Vifor Pharma, Inc.$564
- OPKO Pharmaceuticals, LLC$538
- plus $4K from 28 others
What the payments were for
- Food & beverage$10,60797%
- Education$3823%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 197 | $2,988 |
| AstraZeneca | 79 | $1,223 |
| ANI Pharmaceuticals, Inc. | 57 | $909 |
| Novo Nordisk | 26 | $597 |
| Vifor Pharma, Inc. | 38 | $564 |
| OPKO Pharmaceuticals, LLC | 34 | $538 |
| Bayer | 30 | $504 |
| Travere Therapeutics, Inc. | 21 | $436 |
| Merck | 30 | $412 |
| Mallinckrodt Hospital Products Inc. | 24 | $394 |
| Ardelyx, Inc. | 18 | $387 |
| Lilly USA, LLC | 26 | $297 |
| Otsuka America Pharmaceutical, Inc. | 11 | $260 |
| Boehringer Ingelheim | 14 | $225 |
| Aurinia Pharma U.S., Inc. | 13 | $215 |
| Mallinckrodt Enterprises LLC | 9 | $195 |
| Novartis | 12 | $186 |
| Calliditas Therapeutics US Inc. | 8 | $155 |
| Sanofi-aventis U.S. LLC | 5 | $72 |
| Daiichi Sankyo Inc. | 5 | $64 |
| GSK | 4 | $61 |
| Arbor Pharmaceuticals, Inc. | 4 | $53 |
| Hikma Pharmaceuticals USA | 3 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| AbbVie | 2 | $33 |
| Akebia Therapeutics Inc | 2 | $32 |
| Cardiovascular Systems Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Pfizer | 1 | $14 |
| Fresenius USA Marketing, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
| Ultragenyx Pharmaceutical Inc. | 1 | $11 |
| Global Blood Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$495
- XPHOZAH 30 MG$125
- Tresiba$125
- (815) Thiola$120
- Ozempic$101
How this compares
$10,990 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 98 | $82,366 |
| TrulicityDulaglutide | 53 | $69,635 |
| FarxigaDapagliflozin Propanediol | 86 | $63,927 |
| JardianceEmpagliflozin | 41 | $48,344 |
| JanuviaSitagliptin Phosphate | 56 | $34,403 |
| TradjentaLinagliptin | 51 | $29,197 |
| OzempicSemaglutide | 24 | $27,365 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $22,279 |
| Sevelamer Carbonate | 70 | $18,855 |
| EliquisApixaban | 17 | $18,566 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $16,344 |
| VeltassaPatiromer Calcium Sorbitex | 24 | $14,940 |
| RayaldeeCalcifediol | 11 | $14,716 |
| Lanthanum Carbonate | 14 | $11,287 |
| Budesonide ErBudesonide | 15 | $6,658 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $225 | $83,909105 claims |
| BayerKerendia | $504 | $82,36698 claims |
| MerckJanuvia, Janumet, Janumet Xr | $412 | $73,02784 claims |
| AstraZenecaFarxiga, Lokelma | $1,223 | $70,491102 claims |
| Lilly USA, LLCTrulicity | $297 | $69,63553 claims |
| Novo NordiskOzempic | $597 | $27,36524 claims |
| PfizerEliquis | $14 | $18,56617 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $538 | $14,71611 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $53 | $5,60516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in West Orange
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.